Failure of platelet markers to evaluate membrane biocompatibility during a combined hemodialysis-hemoperfusion treatment.
Plasma levels of the platelet markers beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) are among the most sophisticated indexes of biocompatibility available to evaluate new members for hemodialysis. This investigation was designed to determine the extent of platelet activation by measuring the alpha-granule release products, beta-TG and PF4; anticoagulation and thrombogenesis by monitoring plasma heparin; and fibrinopeptide A (FPA) and thromboxane B2 (TX B2) levels during treatment with a combined hemodialysis-hemoperfusion system. Both in vivo and in vitro results showed that the platelet markers had a pattern different from that generally observed during treatment with hemodialysis alone. This is due to the avidity of charcoal for the markers studied, which therefore cannot be used to evaluate the biocompatibility of the system.
D001672:Biocompatible Materials; D006440:Hemofiltration; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000502:physiology*; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood / Q000628:therapy*; D001620:beta-Thromboglobulin / Q000097:blood*
D001672:Biocompatible Materials; D008567:Membranes, Artificial; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4